Spotlight Innovation

Last updated
Spotlight Innovation Inc.
Company type Public
Inactive
Industry Health care
Founded2006 (2006)(as American Exploration Corp.) [1]
Headquarters
Urbandale, Iowa
,
US
Key people
John Krohn (CEO, President, COO)

Spotlight Innovation Inc. (OTCQB: STLT) [STATUS CLOSED] was an American pharmaceutical holding company. [2] [3] [4] The company maintained two subsidiaries: Caretta Therapeutics, Inc. [5] and Celtic Biotech Iowa, Inc. [6] Spotlight Innovation Inc. is based in Urbandale, Iowa and was publicly traded on the OTCQB marketplace under the stock ticker symbol, STLT. [3] [7]

Contents

History

Spotlight Innovation Inc. was founded in 2012 [8] as Spotlight Innovation, LLC. It became its current iteration in December 2013 after a merger with American Exploration Corp. (AEXP), which had been founded in 2006. At the time of the merger, the new entity, Spotlight Innovation Inc., named Cristopher Grunewald the chief executive officer. [1] [9] The Financial Industry Regulatory Authority approved the name change and the merger on December 16, 2013. [3] Spotlight Innovation began trading on the OTCQB marketplace as STLT in January 2014. [10] In May 2017, Spotlight Innovation announced that Mr. Grunewald had resigned as CEO and that John Krohn, the company's President and Chief Operating Officer, had been appointed as the interim CEO. [11]

In 2014, Spotlight Innovation founded Celtic Biotech Iowa, Inc., as a subsidiary and entered into a share exchange agreement with Celtic Biotech LTD (since rescinded), an Ireland-based pharmaceutical company developing products for the treatment of cancer and pain. According to the terms of the agreement, Celtic Biotech LTD became a subsidiary of Celtic Biotech Iowa, Inc. and was also granted access to Spotlight Innovation's commercialization and business development services. [6] [12] In April 2015, Celtic Biotech Iowa's first product, a formulation developed to facilitate topical delivery of drugs called EPISORB, was registered with the Food and Drug Administration and incorporated into the Pharmacy Benefit Managers database.; [2] [13] In Sept. 2018 the Directors of Celtic Biotech Ltd rescinded its share exchange agreement with Spotlight Innovation for just cause.

In March 2015, Spotlight entered into a purchase agreement with Memcine Pharmaceuticals, Inc., a Coralville, Iowa-based biotech company specializing in vaccine efficacy. [14] Memcine Pharmaceuticals would officially become a Spotlight Innovation subsidiary in June 2015. [5] In April 2015, Spotlight Innovation secured $2.5 million in financing from an unsecured convertible promissory note. [4] In October 2016, Spotlight Innovation announced that it was discontinuing the Memcine Pharmaceuticals Immunoplex development program. [15]

In August 2016 Spotlight Innovation entered into a sponsored research agreement with Florida State University to support the work of Professor Hengli Tang in the development of treatments for Zika virus infection. [16]

In October 2016, Spotlight Innovation announced the formation of subsidiary Caretta Therapeutics, LLC. Caretta Therapeutics is based in Urbandale, Iowa. The subsidiary develops and markets over-the-counter (OTC) analgesic products formulated to provide relief from chronic pain associated with inflammation.

In October 2016, Spotlight Innovation obtained an exclusive license from Indiana University Research and Technology Corp to commercialize an orally available small molecule named STL-182 with potential therapeutic potential for the treatment of spinal muscular atrophy. Early preclinical testing of STL-182 was accomplished by Dr. Elliot Androphy of Indiana University School of Medicine and Professor Kevin Hodgetts of Brigham and Women's Hospital. [17]

In November 2016, Celtic Biotech Ltd received approval from the French National Agency for the Safety of Medicines and Health Products to commence Part 2 of the Phase 1 dose escalation safety study Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. [18]

In December 2016, Spotlight Innovation announced the formation of a Scientific Advisory Board. The board includes Professor Hengli Tang of Florida State University, Dr. Elliot Androphy of Indiana University School of Medicine and Professor Kevin Hodgetts of Brigham and Women's Hospital.

In June 2017, Spotlight Innovation entered into a sponsored research agreement with Brigham and Women's Hospital in support of research conducted by Professor Kevin Hodgetts, Ph.D., intended to develop drugs for the treatment of spinal muscular atrophy. [19]

In August 2017, Spotlight Innovation announced that its subsidiary Caretta Therapeutics had developed its first commercially available over-the-counter analgesic product for the treatment of chronic pain but the product was never launched.

In August 2017, Spotlight Innovation entered into a sponsored research agreement with Indiana University in support of research conducted by Dr. Elliot Androphy intended to develop drugs for the treatment of spinal muscular atrophy. [20]

Subsidiaries

Spotlight Innovation seeks out partnerships and acquisition possibilities with companies developing medical technologies in fields like pharmaceuticals, devices and equipment, and diagnostic products. [1] Currently, Spotlight Innovation has two subsidiary companies: Celtic Biotech Iowa, Inc. and Caretta Therapeutics, LLC.[ citation needed ]. Celtic Biotech Ltd is no longer associated with Spotlight Innovation or its subsidiary, Celtic Biotech Iowa.

Celtic Biotech Iowa, Inc.

Celtic Biotech Iowa's subsidiary, Celtic Biotech LTD, was founded in Dublin, Ireland in 2003 by brothers John Reid and Dr. Paul Reid (the latter of whom serves as the president of Celtic Biotech). [21] Celtic Biotech made headlines in 2011 when they announced a clinical trial to test the effectiveness of Crotoxin, a protein found in South American rattlesnake venom, that could cause cell death in malignant cancer cells. [21] [22] [23] [24] Crotoxin was tested on patients in the George Pompidou University Hospital in Paris. [21] [22] [23] [25]

In 2014, Celtic Biotech LTD entered into a share exchange agreement with Spotlight Innovation's wholly owned subsidiary, Celtic Biotech Iowa, Inc. Celtic Biotech LTD also became a subsidiary of Celtic Biotech Iowa. [6] Since then, Celtic Biotech Iowa has produced the commercial product, EPISORB, a topical gel formulated to deliver drugs transdermally. [2] [13] The company also licensed a cardiotoxin therapy for acute and chronic nephropathy in 2015.[ citation needed ] In January, 2015, Celtic Biotech Iowa was granted a patent by the U.S. Patent and Trademark Office entitled Crotoxin Administration for Cancer Treatment and Pain Relief. [26] [27] In July 2015, the company entered into a research agreement with Atlanta-based Emory University to study the viability of the cell-penetrating peptide Crotamine—a protein found in the venom of the South American rattlesnake, crotalus durissus terrificus —as a radiopharmaceutical for imaging lung cancer tumors with Positron Emission Tomography (PET). [28] In Sept. 2018 the Directors of Celtic Biotech Ltd rescinded its share exchange agreement with Spotlight Innovation for just cause.

Caretta Therapeutics, LLC

Spotlight Innovation's subsidiary Caretta Therapeutics was founded in 2016. The subsidiary entered into a licensing agreement with Dr. Paul Reid for rights to develop and commercialize analgesic products for the treatment of chronic pain utilizing active ingredient cobra venom. In August 2017, Caretta Therapeutics began the manufacture of its first product, Venodol roll-on, under the licensing agreement but sales were not undertaken.

Related Research Articles

<span class="mw-page-title-main">Novartis</span> Swiss multinational pharmaceutical corporation

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.

Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.

<span class="mw-page-title-main">AstraZeneca</span> British pharmaceutical company

AstraZeneca plc (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

<span class="mw-page-title-main">Roche</span> Swiss multinational healthcare company

F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.

<span class="mw-page-title-main">Gilead Sciences</span> American pharmaceutical company

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.

<span class="mw-page-title-main">Biocon</span> Indian multinational biopharmaceutical company

Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.

<span class="mw-page-title-main">Eisai (company)</span> Japanese pharmaceutical company

Eisai Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.

Takeda Oncology is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.

<span class="mw-page-title-main">Celgene</span> American biopharmaceutical company

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).

C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.

<span class="mw-page-title-main">Astellas Pharma</span> Japanese pharmaceutical company

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd.. On February 5, 2020, the company announced management changes effective from April 1, 2020.

<span class="mw-page-title-main">Basilea Pharmaceutica</span> Swiss pharmaceutical company

Basilea Pharmaceutica is a multinational specialty biopharmaceutical company headquartered in Basel, Switzerland. It was formed as a spin-off entity from the drug giant Hoffmann–La Roche in October 2000. It is engaged in the development of antibiotics, antifungals and oncology drugs for treatment of invasive aspergillosis and mucormycosis. Basilea is publicly traded on the SIX Swiss exchange.

<span class="mw-page-title-main">Merck & Co.</span> American multinational pharmaceutical company

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.

<span class="mw-page-title-main">United Therapeutics</span> American biotech company based in Maryland

United Therapeutics Corporation is an American publicly traded biotechnology company and public benefit corporation listed on the NASDAQ under the symbol UTHR. It develops novel, life-extending technologies for patients in the areas of lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire.

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company’s seat in Forbes Global 2000 was 74. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

<span class="mw-page-title-main">Moderna</span> American biotechnology company

Moderna, Inc. is a pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

<span class="mw-page-title-main">Sotio</span>

SOTIO Biotech is a Czech biotechnology company focused on clinical-stage research and development of innovative medicines for cancer with operations in Europe, North America, and Asia. The company has clinical programs which include a superagonist of the immuno-oncology target IL-15, a new generation of potent and stable antibody-drug conjugates (ADCs), proprietary technology designed to improve on the efficacy of CAR T therapies and a platform to streamline and enhance personalized cell therapies.

<span class="mw-page-title-main">Hanmi Pharm</span> South Korean pharmaceutical company

Hanmi Pharm Co., Ltd. is a South Korean pharmaceutical company that is headquartered in Seoul.

<span class="mw-page-title-main">Fortress Biotech</span>

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

<span class="mw-page-title-main">CRISPR Therapeutics</span> Swiss-American biotechnology company

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.

References

  1. 1 2 3 "Spotlight Innovation, Inc. Announces Name Change and Closing of Merger". MarketWatch . 12 December 2013. Retrieved 14 August 2015.
  2. 1 2 3 "West Des Moines medical IP company advances product". Business Record. 16 April 2015. Retrieved 14 August 2015.
  3. 1 2 3 "Spotlight Innovation's Name Change, Symbol Change and Reverse Split Approved by FINRA". MarketWatch . 16 December 2013. Retrieved 14 August 2015.
  4. 1 2 "West Des Moines IP incubator company secures $2.5 million in financing". Business Record. 29 April 2015. Retrieved 14 August 2015.
  5. 1 2 "Spotlight Innovation acquires majority stake in Memcine Pharmaceuticals". Business Record. 9 June 2015. Retrieved 14 August 2015.
  6. 1 2 3 "Spotlight Innovation Subsidiary Celtic Biotech Iowa, Inc. Completes Merger With Celtic Biotech Ltd". MarketWatch . 10 June 2014. Retrieved 14 August 2015.
  7. ↑ "Spotlight Innovation, Inc". Otcmarkets.com. OTC Markets Group . Retrieved 14 August 2015.
  8. ↑ "Company Overview of Spotlight Innovation, Inc". Bloomberg.com. Bloomberg . Retrieved 14 August 2015.
  9. ↑ "Spotlight Innovation CEO to Speak at BioNetwork West Partnering Summit October 26-28, 2015". CNNMoney. 14 August 2015. Retrieved 14 August 2015.
  10. ↑ "Important Notice" (PDF). Depository Trust & Clearing Corporation. 17 January 2014. Retrieved 7 September 2015.
  11. ↑ "About Us - IP Biotechnology Investing - Spotlight Innovation". Spotlightinnovation.com. Retrieved 2 June 2019.
  12. ↑ "Company Overview of Celtic Biotech Ltd". Bloomberg.com. Bloomberg . Retrieved 14 August 2015.
  13. 1 2 "Celtic Biotech Iowa Requests Reactivation and Transfer of National Drug Code Registration". GuruFocus. 4 December 2014. Retrieved 14 August 2015.
  14. ↑ "STLT Spotlight Innovation Enters Into Purchase Agreement With Memcine Pharmaceuticals". OTC Dynamics. 17 March 2015. Retrieved 14 August 2015.
  15. ↑ "About Us - IP Biotechnology Investing - Spotlight Innovation". Ir.spotlightinnovation.com. Retrieved 2 June 2019.
  16. ↑ "FSU scientists ink deals to send technologies to marketplace". News.fsu.edu. 11 July 2017. Retrieved 2 June 2019.
  17. ↑ "Rights to Potential SMA Treatment Aiming at SMN Gene Acquired by Spotlight". Smanewstoday.com. 22 November 2016. Retrieved 2 June 2019.
  18. ↑ "Open Label Clinical Trial of Intravenous Crotoxin - Full Text View". Clinicaltrials.gov. Retrieved 2 June 2019.
  19. ↑ Wood, Megan (30 June 2017). "Brigham and Women's Hospital, Spotlight Innovation partner to support Dr. Kevin Hodgetts' spinal muscular atrophy research: 5 things to know". Beckersspine.com. Retrieved 2 June 2019.
  20. ↑ "Spotlight Innovation signs research agreement with Indiana University to develop new therapies for SMA". Pharmabiz.com. Retrieved 2 June 2019.
  21. 1 2 3 O'Halloran, Barry (28 October 2011). "Celtic Biotech to start snake venom cancer drug trials". The Irish Times . Retrieved 14 August 2015.
  22. 1 2 Boyle, Rebecca (17 November 2011). "In First Clinical Trial, Unemployed Rattlesnakes Find Work as Cancer-Fighters". Popular Science . Retrieved 14 August 2015.
  23. 1 2 Kelly, Dara (29 October 2011). "Irish biotech company to begin snake venom cancer drug trials". IrishCentral. Retrieved 14 August 2015.
  24. ↑ "Toxic medicine". The Economist . 5 January 2013. Retrieved 14 August 2015.
  25. ↑ "Health in Iowa" . Retrieved 20 February 2019.
  26. ↑ USpatent 2013129706A1,"Crotoxin Administration for Cancer Treatment and Pain Relief"
  27. ↑ "Spotlight Innovation Subsidiary Celtic Biotech Iowa Granted Patent by the U.S. Patent and Trademark Office". MarketWatch . 15 January 2015. Retrieved 7 September 2015.
  28. ↑ "Spotlight Innovation Subsidiary Celtic Biotech Enters Into Research Agreement With Emory University". Andhra News. 6 July 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.